Gerresheimer: Bormioli Pharma boosts revenues and earnings

-­ Revenues +11.6%, Adjusted EBITDA +13.1%

­- Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3%

-­ Q1 significantly influenced by revenue shift in syringe business

­- Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22%

DÜSSELDORF, Germany, April 11, 2025 /PRNewswire/ -- Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, recorded a jump in revenues and earnings due to the first-time consolidation of Bormioli Pharma, which was acquired in 2024. Revenues in the first quarter of 2025 rose by 11.6% to EUR 520.1 million (Q1 2024: EUR 466.1 million), while adjusted EBITDA increased by 13.1% to EUR 91.5 million (Q1 2024: EUR 80.9 million). The organic development compared to the pro forma figures for the prior-year quarter reflects a shift in revenues in the syringe business and subdued demand for moulded glass especially from the cosmetics sector. In organic terms, revenues fell by 6.5% in the first quarter of 2025 compared to the first quarter of 2024, while adjusted EBITDA declined by 9.3%. The adjusted EBITDA margin was 17.6% (Q1 2024: 17.4%). Based on existing contracts with further production ramp-ups in the course of the year and the good order intake from the first quarter of 2025, Gerresheimer confirms its guidance for the financial year 2025. The Group, including Bormioli Pharma, expects organic revenue growth of 3-5% compared to the combined pro forma figures for 2024. The adjusted EBITDA margin is expected to improve further to around 22%.

"With the acquisition of Bormioli Pharma, we have ...

https://www.benzinga.com/pressreleases/25/04/n44754655/gerresheimer-bormioli-pharma-boosts-revenues-and-earnings